Witnessing the stock’s movement on the chart, on Wednesday, Relmada Therapeutics Inc (NASDAQ: RLMD) set off with pace as it heaved 6.68% to $0.30, before settling in for the price of $0.29 at the close. Taking a more long-term approach, RLMD posted a 52-week range of $0.28-$7.22.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 0.00% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -2.94%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 16.46%. This publicly-traded company’s shares outstanding now amounts to $30.17 million, simultaneously with a float of $25.28 million. The organization now has a market capitalization sitting at $9.20 million. At the time of writing, stock’s 50-day Moving Average stood at $0.5519, while the 200-day Moving Average is $2.5862.
Relmada Therapeutics Inc (RLMD) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Relmada Therapeutics Inc’s current insider ownership accounts for 16.22%, in contrast to 38.50% institutional ownership. According to the most recent insider trade that took place on Sep 11 ’24, this organization’s Chief Executive Officer bought 51,407 shares at the rate of 2.99, making the entire transaction reach 153,707 in total value, affecting insider ownership by 384,024. Preceding that transaction, on Sep 09 ’24, Company’s Chief Executive Officer bought 55,579 for 2.71, making the whole transaction’s value amount to 150,619. This particular insider is now the holder of 299,603 in total.
Relmada Therapeutics Inc (RLMD) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Relmada Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 16.46% and is forecasted to reach -1.15 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 25.49% through the next 5 years, which can be compared against the -2.94% growth it accomplished over the previous five years trading on the market.
Relmada Therapeutics Inc (NASDAQ: RLMD) Trading Performance Indicators
Let’s observe the current performance indicators for Relmada Therapeutics Inc (RLMD). It’s Quick Ratio in the last reported quarter now stands at 6.89. The Stock has managed to achieve an average true range (ATR) of 0.06.
In the same vein, RLMD’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.87, a figure that is expected to reach -0.71 in the next quarter, and analysts are predicting that it will be -1.15 at the market close of one year from today.
Technical Analysis of Relmada Therapeutics Inc (RLMD)
Going through the that latest performance of [Relmada Therapeutics Inc, RLMD]. Its last 5-days volume of 6.38 million indicated improvement to the volume of 1.63 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 8.03% While, its Average True Range was 0.0449.
Raw Stochastic average of Relmada Therapeutics Inc (RLMD) in the period of the previous 100 days is set at 0.67%, which indicates a major fall in contrast to 11.99% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 91.10% that was lower than 251.66% volatility it exhibited in the past 100-days period.
